Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
Dexcom announced positive results from the CONNECT randomized controlled trial, showing that Dexcom G7 leads to a clinically significant 1.6% average A1C reduction in Type 2 diabetes patients not using insulin. The study demonstrated a 0.9% greater A1C reduction compared to the control group using self-monitoring of blood glucose, with even larger benefits (3.1% reduction) for patients with baseline A1C >10%.
Key figures
- Drug Name
- Dexcom G7
- Phase Of Trial
- Randomized Controlled Trial
- A1c reduction avg
- 1.6%
- Daily usage median
- 97%
- Study duration weeks
- 26
- Time in range dexcom
- 62%
- Time in range control
- 41%
- Participants completed
- 265
- Participants randomized
- 283
- A1c reduction vs control
- 0.9%
- Time in range improvement
- 5 hours/day
- A1c reduction high baseline
- 3.1%
- Participants reaching a1c lt 7.0
- 46%
- Participants reaching a1c lt 7.5
- 68%
- A1c reduction high baseline vs control
- 2.1%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.